About this document
Vericiguat by cortezoscar214 is a document available to read on EtoBox.
The VICTOR trial assessed the efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction (HFrEF) without recent worsening events. The study found no statistically significant reduction in the primary composite endpoint of cardiovascular death or heart failure hospitalisation between the vericiguat and placebo groups, although fewer cardiovascular deaths were observed in the vericiguat group. The trial highlights the need for further research on vericiguat
- Author
- cortezoscar214
- Language
- EN